Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022"

Sieta T de Vries^{1

2}, Noral Huda S Al-Mugoter¹, Irena Petkoska¹, Stefan Verweij^{1

3}, André J A Elferink¹, Peter G M Mol^{4

5}

Affiliations

¹ Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
² Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
³ Department of Pharmacotherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands.
⁴ Dutch Medicines Evaluation Board, Utrecht, The Netherlands. p.g.m.mol@umcg.nl.
⁵ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. p.g.m.mol@umcg.nl.

Comment

Sieta T de Vries et al. Appl Health Econ Health Policy. 2024 Jan.

. 2024 Jan;22(1):123-124.

doi: 10.1007/s40258-023-00850-4. Epub 2023 Nov 16.

Sieta T de Vries^{1

2}, Noral Huda S Al-Mugoter¹, Irena Petkoska¹, Stefan Verweij^{1

3}, André J A Elferink¹, Peter G M Mol^{4

5}

¹ Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
² Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
³ Department of Pharmacotherapy, Epidemiology and Economics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, The Netherlands.
⁴ Dutch Medicines Evaluation Board, Utrecht, The Netherlands. p.g.m.mol@umcg.nl.
⁵ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. p.g.m.mol@umcg.nl.

No abstract available

Comment on

The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022.
Meregaglia M, Malandrini F, Angelini S, Ciani O. Meregaglia M, et al. Appl Health Econ Health Policy. 2023 Nov;21(6):925-935. doi: 10.1007/s40258-023-00827-3. Epub 2023 Sep 2. Appl Health Econ Health Policy. 2023. PMID: 37659000 Free PMC article. Review.

1. Meregaglia M, Malandrini F, Angelini S, Ciani O. The assessment of patient-reported outcomes for the authorisation of medicines in Europe: a review of European Public Assessment Reports from 2017 to 2022. Appl Health Econ Health Policy. 2023. https://doi.org/10.1007/s40258-023-00827-3 . - DOI - PubMed - PMC
1. European Medicines Agency (EMA). European Public Assessment Reports. https://www.ema.europa.eu/en/medicines/download-medicine-data . Accessed 13 July 2023.
1. Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM, NCIC CTG Quality of Life Committee. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):119–28. https://doi.org/10.1586/erp.10.15 . - DOI - PubMed
1. Haag S, Junge L, Lotz F, McGauran N, Paulides M, Potthast R, Kaiser T. Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs. J Patient Rep Outcomes. 2021;5(1):127. https://doi.org/10.1186/s41687-021-00402-1 . - DOI - PubMed - PMC